Investor Centre

Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
Stat background
0.24 GBX Volume: 77,143 Market Capitalisation (m) £5.07

TheraCryf plc Investor Presentation

09 - July - 2025
TheraCryf shares the corporate presentation following the AGM held on the 9th July 2025.

Voting on AGM Resolutions

09 - July - 2025
Results of the voting released following the AGM on the 9th July 2025

AGM Presentation

10 - July - 2025
TheraCryf's leadership team present the latest updates following the AGM on the 9th July.

Major Shareholders

Current ShareholderNumber of sharesPercentage holding
Northern Standard Limited422,727,27219.67%
First Equity Limited179,000,0008.33%
T and I Limited160,000,0007.45%
Spreadex Limited93,050,0014.33%
Oberon Investments Limited 80,475,0003.74%
A Leach80,000,0003.72%
S Gibeon71,400,0003.32%
J. R. Kight56,100,000 2.61%
Rathbones Investment Management Ltd24,835,7041.16%
Octopus Investments21,875,0001.02%
Vulpes Investment Management Pte Ltd20,554,1910.96%
Seneca Partners Limited16,301,4560.76%
The number of ordinary shares in issue is 2,148,963,739. Directors hold 13,184,793 and 2,135,778,946 are in public hands. The Company does not hold any shares in the Treasury.
Last updated 25 June 2025